How E-Commerce Returns Can Be Maximized

 

Key Points:

  1. E-commerce platforms like Happy Returns are viable options for online retailers that don’t have a physical store presence or small store footprints to provide more return choices
  2. It doesn’t make economic sense to invest in stand alone return centers for most retailers and brands except for a few large ones
  3. Partnership between brick & mortar and e-commerce platforms is a win for the shopper the retailer and the brick & mortar retail partner that’s facilitating the returns in store

Commentary:

E-commerce is constantly changing how business is done. For some consumers returning items bought on e-commerce platforms can be difficult especially when there isn’t a physical store presence to go to. With platforms like Happy Return, a company that specializes in helping consumers make returns, solutions to this problem are starting to be found. MarketScale asked Meyar Sheik, President & Chief Commerce Officer at Kibo: Are e-commerce platforms like Happy Returns the most viable option to provide more return choices for online retailers that don’t have a physical store presence or small store footprints?

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More